{"name":"Centre Europeen d'Etude du Diabete","slug":"centre-europeen-d-etude-du-diabete","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Basal-bolus detemir-aspart insulin regimen","genericName":"Basal-bolus detemir-aspart insulin regimen","slug":"basal-bolus-detemir-aspart-insulin-regimen","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Basal-bolus detemir-aspart insulin regimen","genericName":"Basal-bolus detemir-aspart insulin regimen","slug":"basal-bolus-detemir-aspart-insulin-regimen","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOd3RMaHZrX1RYOElSYURvU2dnSGZJYkRGNVJWckYwR1F1NndtLTg0STBqTVlFQ3dZS2hEak1iRy1ELW5kZXZfdHNVVGZLcExWN3ZxSGZZZGdMcENQdTdOVV9XLUg0dTRVY1lKWVFyZF9jT0tRMldSaUVicnZDMG00cUlWOWFrNWVtLXdTTEVOTnVmcWlaTVd0dVM5UVVGbkJWTU1yMjJfUXBYNXRYTEhyYzI0RzI4NGlFTHItcmln?oc=5","date":"2024-07-05","type":"pipeline","source":"ANSM","summary":"Actualité - Analogues du GLP-1 : point sur la surveillance des effets indésirables graves et mésusages - ANSM","headline":"Actualité - Analogues du GLP-1 : point sur la surveillance des effets indésirables graves et mésusages","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}